NEW YORK and LONDON, June 9 /PRNewswire/ -- Paul Capital Healthcare today announced that London-based partner Ken Macleod, Ph.D., will moderate a panel on strategic biotechnology financing at the BioFinance and BioInnovate Europe 08 conference. Designed to familiarize participants with how to use revenue streams as a strategic approach to financing, the panel, "Feeding the Beast: Structured Revenue Financing as a Strategy for Meeting Biotechnology's Capital Needs," is scheduled for 3:00 pm BST today. The conference, which is sponsored by the Biotechnology Industry Association, will be held at the Royal College of Physicians in London.
In addition to Dr. Macleod, the panel also will include Kristian Wiggert, Partner in the London office of Morrison & Foerster, and Steven Powell, Ph.D., Chief Executive Officer of Plethora Solutions Holdings PLC. Dr. Macleod will provide an overview and case studies of royalty and structured revenue financing transactions, Mr. Wiggert will discuss the legal considerations of these transactions and Dr. Powell will speak on the strategic rationale and mechanics of his company's recent revenue interest agreement with Paul Capital Healthcare.
"Structured revenue financing and royalty monetization transactions are becoming a standard financing strategy because they provide access to non- dilutive capital under flexible terms that can be structured to meet diverse objectives," said Dr. Macleod. "Companies and institutions can structure these transactions to provide capital for near-term initiatives while retaining a substantial portion of the long-term value and upside potential of their royalty and revenue streams. This panel presentation is designed to provide participants with real-life examples of how these transactions fit into an overall financial and asset management strategy and the opportunity to learn from those with first-hand knowledge of the process."
About Paul Capital Healthcare and Paul Capital Partners
Through its funds, Paul Capital Healthcare is one of the largest
dedicated healthcare investors globally, with more than $1.4 billion in
equity capital commitments and debt facilities under management. Combined,
the Paul Capital Healthcare funds have invested more than $940 million in
the pharmaceutical, biotechnology, and medical device sectors. These
investments are focused on commercial stage companies and products, and
consist of investments in the form of royalties, revenue interests, debt
and equity. Additional information on Paul Capital Healthcare can be found
at http://www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly $5
billion in equity capital commitments for its three investment platforms,
which include Paul Capital Healthcare, Private Equity Secondaries and Top
Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris,
London, Hong Kong, and Sao Paolo.
Paul Capital Healthcare Tel: +44 (0) 20 7514 0754
Ken Macleod, Partner
Lazar Partners Tel: +1-646-871-8487
Stephanie Seiler Tel: +1-206-713-0124
|SOURCE Paul Capital Healthcare|
Copyright©2008 PR Newswire.
All rights reserved